AR077484A1 - Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion - Google Patents

Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion

Info

Publication number
AR077484A1
AR077484A1 ARP100102598A ARP100102598A AR077484A1 AR 077484 A1 AR077484 A1 AR 077484A1 AR P100102598 A ARP100102598 A AR P100102598A AR P100102598 A ARP100102598 A AR P100102598A AR 077484 A1 AR077484 A1 AR 077484A1
Authority
AR
Argentina
Prior art keywords
glatiramer acetate
mannitol
administration
solution
aqueous pharmaceutical
Prior art date
Application number
ARP100102598A
Other languages
English (en)
Spanish (es)
Inventor
Ayelet Altman
Doris Saltkill
Tomar El-Gad
Dalton L Tomlinson
David George Robinson
Paul Greenhalgh
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077484(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR077484A1 publication Critical patent/AR077484A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP100102598A 2009-07-15 2010-07-15 Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion AR077484A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29
US12/761,367 US20110060279A1 (en) 2009-07-15 2010-04-15 Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration

Publications (1)

Publication Number Publication Date
AR077484A1 true AR077484A1 (es) 2011-08-31

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100102598A AR077484A1 (es) 2009-07-15 2010-07-15 Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion

Country Status (19)

Country Link
US (3) US20110060279A1 (enExample)
EP (2) EP2275086B1 (enExample)
JP (1) JP2012533540A (enExample)
AR (1) AR077484A1 (enExample)
AT (1) ATE549013T1 (enExample)
AU (1) AU2010273234A1 (enExample)
BR (1) BR112012000878A2 (enExample)
CA (1) CA2697570C (enExample)
DK (1) DK2275086T3 (enExample)
EA (1) EA201270167A1 (enExample)
ES (1) ES2383347T3 (enExample)
HR (1) HRP20120349T1 (enExample)
IL (1) IL217240A0 (enExample)
MX (1) MX2012000687A (enExample)
PL (1) PL2275086T3 (enExample)
PT (1) PT2275086E (enExample)
RS (1) RS52367B (enExample)
WO (1) WO2011008274A2 (enExample)
ZA (1) ZA201200586B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
HUE031282T2 (hu) 2009-08-20 2017-06-28 Yeda Res & Dev Alacsony gyakoriságú glatiramer acetát terápia
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
KR101694645B1 (ko) * 2012-08-20 2017-01-09 케어베이 유럽 리미티드 자동 주입 장치
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
AU2014229581B2 (en) * 2013-03-08 2016-12-22 Teva Pharmaceutical Industries Limited Re-useable injector device for syringe
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
PE20151577A1 (es) * 2013-03-08 2015-11-19 Teva Pharma Dispositivo inyector reutilizable para jeringa
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP6550393B2 (ja) 2014-02-26 2019-07-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼内インプラント送出装置及び使用方法
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
CA3042493A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3673317D1 (de) * 1985-10-11 1990-09-13 Duphar Int Res Automatische spritze.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) * 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
WO2004047893A1 (de) * 2002-11-25 2004-06-10 Tecpharma Licensing Ag Autoinjektor mit rückstellbarer auslösesicherung
WO2005032482A2 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
WO2006050122A1 (en) * 2004-10-29 2006-05-11 Sandoz Ag Processes for preparing glatiramer
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
TWI542374B (zh) * 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
US20090149541A1 (en) 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
CA2697570C (en) * 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration

Also Published As

Publication number Publication date
AU2010273234A1 (en) 2012-02-23
US20110066112A1 (en) 2011-03-17
RS52367B (sr) 2012-12-31
CA2697570A1 (en) 2010-06-22
CA2697570C (en) 2011-11-01
HK1152249A1 (en) 2012-02-24
EP2275086A1 (en) 2011-01-19
WO2011008274A3 (en) 2011-09-22
IL217240A0 (en) 2012-02-29
ES2383347T3 (es) 2012-06-20
DK2275086T3 (da) 2012-07-09
PL2275086T3 (pl) 2012-09-28
ZA201200586B (en) 2013-10-30
HRP20120349T1 (hr) 2012-07-31
US9018170B2 (en) 2015-04-28
JP2012533540A (ja) 2012-12-27
ATE549013T1 (de) 2012-03-15
US20110060279A1 (en) 2011-03-10
EP2275086B1 (en) 2012-03-14
WO2011008274A4 (en) 2011-11-10
BR112012000878A2 (pt) 2019-09-24
WO2011008274A2 (en) 2011-01-20
MX2012000687A (es) 2012-09-07
EA201270167A1 (ru) 2012-08-30
US7855176B1 (en) 2010-12-21
PT2275086E (pt) 2012-05-18
EP2453907A2 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
AR077484A1 (es) Formulacion de acetato de glatiramer de volumen reducido y metodos para su administracion
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
BRPI0707235B8 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
BRPI0910341A8 (pt) dispositivo para conservação, preparação espontanea e administração de um principio ativo
ES2904543T3 (es) Tratamiento de la disfunción sexual
MX386614B (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
JP2015513309A5 (enExample)
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX2019007779A (es) Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe).
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Bowe et al. Therapeutic update: acne
RU2011139015A (ru) Вызываемая медикаментозными средствами липоатрофия для косметических целей
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno

Legal Events

Date Code Title Description
FB Suspension of granting procedure